March 15, 2022 -- Catamaran Bio has expanded its research collaboration with the University of Minnesota to advance transposon engineering for CAR-NK cell therapies. The company also said it secured an exclusive, worldwide license to University of Minnesota's patent rights covering next-generation cell expansion technologies.
The cell expansion technologies under the patent do not require the use of feeder cells; these technologies have the potential to improve the efficiency and decrease the cost of manufacturing CAR-NK cell therapies, the company said.
The collaboration, which is with Branden Moriarity, PhD, of the University of Minnesota, will further optimize the TcBuster transposon system, a next-generation nonviral genetic modification system that has been integrated into Catamaran's TAILWIND platform.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
